AstraZeneca, lung cancer drug trial
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
Chinese authorities detained some current and former employees of AstraZeneca Plc (NASDAQ:AZN) as part of a broader investigation into alleged illegal activities in the pharmaceutical sector. The investigation focuses on potential breaches of data privacy laws and the importation of unlicensed cancer medications.
Lung cancer drug trial results hit AstraZeneca shares
Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation lung cancer drug set back its ambitions to offer precision oncology treatments to more patients.
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
AstraZeneca shares slumped after its key lung-cancer drug trial failed necessary targets that could risk U.S. Food & Drug Administration approval in the coming weeks. AstraZeneca shares slid 5% to 121.
AstraZeneca stock drops after lung cancer drug trial setback
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.
AstraZeneca Sees Positive Survival Data in Recent Lung-Cancer-Treatment Trials
AstraZeneca said Monday that recent phase-three trials for its lung-cancer-treatment datopotamab deruxtecan showed a clinically meaningful trend toward improving overall survival. The pharmaceutical company said the treatment showed median overall survival of nearly 15 months in patients with advanced nonsquamous non-small cell lung cancer that were observed in the Tropion-Lung01 Phase III trial.
AstraZeneca shares drop as lung cancer drug trial fails to improve survival
London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.
Bloomberg Talks: Astrazeneca CEO Claude Roland Soriot
Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...
AstraZeneca (LSE:AZN) Gains FDA Approval for Fasenra in EGPA, Boosting Revenue Growth and Market Position
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
Fortune LGBTQ+ Leaders: The top 10 ones to watch in the years ahead
What will the LGBTQ+ Leaders of the future look like? Here are some of the names we expect to see a lot more of in the coming ...
FiercePharma13d
AstraZeneca's Alexion loses $130M to Syntimmune shareholders in post-merger payment suit
When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...
AstraZeneca Defends China Compliance In Wake of Staff Detentions
AstraZeneca Plc has strong compliance policies in China and is working closely with authorities following the detention of ...
Becker's Hospital Review8d
Moffitt, AstraZeneca partner on cell therapy development
Tampa, Fla.-based Moffitt Cancer Center and drugmaker AstraZeneca are collaborating to accelerate the development of CAR-T cell and T cell receptor therapies.
Yahoo Finance5d
AstraZeneca PLC (AZNA.VI)
CEO Pascal Soriot said AstraZeneca is compliant with Chinese policies and is working closely with authorities following ...
ENDPOINTS NEWS3d
Bio­Cen­triq names ex-Re­silient ex­ec as new CEO; Sanofi, As­traZeneca boost Bey­for­tus pro­duc­tion
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...